BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16337408)

  • 1. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
    Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
    Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
    Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
    Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
    Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA2 founder mutation in Slovenian breast cancer families.
    Krajc M; De Grève J; Goelen G; Teugels E
    Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations in a South American population.
    Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
    Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 15. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
    Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
    Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.
    Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S
    Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
    Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
    J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer susceptibility testing: past, present and future.
    Goldberg JI; Borgen PI
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.